Deutsche Bank Ag\ 2seventy Bio, Inc. Transaction History

Deutsche Bank Ag\

$240 Billion
Q3 2024

A detailed history of Deutsche Bank Ag\ transactions in 2seventy Bio, Inc. stock. As of the latest transaction made, Deutsche Bank Ag\ holds 1,330,950 shares of TSVT stock, worth $4.18 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,330,950

Previous 1,784,619 25.42%

Holding current value

$4.18 Million

Previous $6.87 Million 8.56%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$3.85 - $5.05 $1.75 Million - $2.29 Million	-453,669 Reduced 25.42%	1,330,950 $6.28 Million
Q2 2024 Aug 14, 2024	BUY	$3.6 - $5.79 $6.34 Million - $10.2 Million	1,762,444 Added 7947.89%	1,784,619 $6.87 Million
Q1 2024 May 15, 2024	SELL	$3.09 - $6.0 $2,555 - $4,962	-827 Reduced 3.6%	22,175 $118,000
Q4 2023 Feb 14, 2024	SELL	$1.57 - $4.58 $4,917 - $14,344	-3,132 Reduced 11.98%	23,002 $98,000
Q3 2023 Nov 09, 2023	BUY	$3.14 - $11.2 $11,106 - $39,614	3,537 Added 15.65%	26,134 $102,000
Q2 2023 Aug 14, 2023	SELL	$8.45 - $12.48 $29,422 - $43,455	-3,482 Reduced 13.35%	22,597 $228,000
Q1 2023 May 15, 2023	BUY	$9.21 - $14.98 $69,185 - $112,529	7,512 Added 40.46%	26,079 $266,000
Q4 2022 Feb 13, 2023	SELL	$8.57 - $17.0 $399,516 - $792,506	-46,618 Reduced 71.52%	18,567 $173,000
Q3 2022 Nov 14, 2022	SELL	$12.56 - $17.54 $54,296 - $75,825	-4,323 Reduced 6.22%	65,185 $949,000
Q2 2022 Aug 11, 2022	BUY	$10.55 - $18.81 $584,111 - $1.04 Million	55,366 Added 391.5%	69,508 $917,000
Q1 2022 May 13, 2022	SELL	$11.67 - $26.72 $318,450 - $729,135	-27,288 Reduced 65.87%	14,142 $241,000
Q4 2021 Feb 11, 2022	BUY	$13.77 - $42.56 $570,491 - $1.76 Million	41,430 New	41,430 $1.06 Million

Others Institutions Holding TSVT

# of Institutions

126

Shares Held

45.6M

Call Options Held

122K

Put Options Held

19.8K

View Full List

About 2seventy bio, Inc.

Ticker TSVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,873,600
Market Cap $119M
Description
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a col...

More about TSVT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.

Account